U.S. markets open in 2 hours 21 minutes
  • S&P Futures

    4,548.50
    +24.25 (+0.54%)
     
  • Dow Futures

    35,062.00
    +152.00 (+0.44%)
     
  • Nasdaq Futures

    15,166.75
    +133.25 (+0.89%)
     
  • Russell 2000 Futures

    2,070.70
    +11.50 (+0.56%)
     
  • Crude Oil

    86.67
    -0.29 (-0.33%)
     
  • Gold

    1,839.80
    -3.40 (-0.18%)
     
  • Silver

    24.27
    +0.04 (+0.18%)
     
  • EUR/USD

    1.1347
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.8270
    0.0000 (0.00%)
     
  • Vix

    23.15
    +0.36 (+1.58%)
     
  • GBP/USD

    1.3598
    -0.0013 (-0.10%)
     
  • USD/JPY

    114.2700
    -0.0830 (-0.07%)
     
  • BTC-USD

    42,026.66
    -151.56 (-0.36%)
     
  • CMC Crypto 200

    998.99
    +4.24 (+0.43%)
     
  • FTSE 100

    7,584.80
    -4.86 (-0.06%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy?

·4 min read
Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

None of them has been a bigger financial winner than Pfizer (NYSE: PFE). SVB Leerink analyst Geoffrey Porges estimates that Pfizer is set to make a stunning $131 billion in COVID-19 sales by the end of 2022. Let's first look at how Pfizer could make $160 billion from COVID-19 within the next two years.